The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2010Developing Circuit-Targeting Optogenetic Strategies for Pre-Clinical Model Motor Circuitry
Objective/Rationale:
Optogenetics is a new technology that allows control of brain cells with light- in a way that allows targeting of control to well-defined subsets of cells in vivo, even if those... -
MJFF Research Grant, 2010Regulation of LRRK2 Membrane Association
Objective/Rationale:
Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. The LRRK2 gene encodes a large multi-domain protein with kinase activity. LRRK2 protein is normally... -
MJFF Research Grant, 2010Patient-specific iPS cell-derived Neurons and Disease-associated LRRK2 Mutations for Parkinson's Disease Research
Objective/Rationale:
Several underlying genetic risk factors are now established for Parkinson’s disease (PD). Mutations in LRRK2 are the most common genetic cause of the selective neurodegeneration... -
MJFF Research Grant, 2010Male transgenic rat Parkinson's disease model characterization
Promising Outcomes of Original Grant:
The original project focused on the creation and characterization of pre-clinical models that express mutations in the protein alpha-synuclein that are known to... -
Rapid Response Innovation Awards, 2010The Role of Alpha-synuclein in the Pathogenesis of Parkinson's Disease in a Pre-clinical Model
Objective/Rationale:
We hypothesized that alpha-synuclein increased level and accumulation within the target neurons in the affected model acts as a trigger mechanism for activation of additional... -
MJFF Research Grant, 2010Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
Objective/Rationale:
Ashkenazi Jewish PD patients in Israel have a 14% chance of carrying the G2019S LRRK2 mutation and 18% of carrying mutations in the GBA gene. Little is known on the association...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.